Lupin rose 1.46% to Rs 2,271.90 after it launched Mirabegron extended-release tablets in the US after receiving an approval from the United States Food and Drug Administration (USFDA).
Subscribe To Our Free Newsletter |
Lupin rose 1.46% to Rs 2,271.90 after it launched Mirabegron extended-release tablets in the US after receiving an approval from the United States Food and Drug Administration (USFDA).
Subscribe To Our Free Newsletter |
EvoLve theme by Theme4Press • Powered by WordPress & Rakesh Jhunjhunwala Latest Stock Market News
The Most Valuable Commodity Is Information!